
Transformation towards higher growth.





Investor Presentation | November 2024

medartis

The market

Medartis today


Transformation towards higher growth

Summary and key takeaways





medartis Extremities – an attractive niche with above average growth



- Projected growth 2024-2030: 4.3%
- Key trends: High incidence of orthopedic disorders, growing aging population, increase in degenerative bone disease, and growing number of road accidents
- US contributes 46% of global sales with 3% \bullet growth; Europe 27% with 4.1% growth; APAC 18% with 6.7% growth, and Latam 8% with 5% growth


Elbow & shoulder* 13% Hand & wrist 22%

- Projected growth 2024-32: ~7%
- currently cover
- cover


Source: DRG, OrthoWorld, own research

Investor Presentation | November 2024

Addressable market by segment ('24E)



Addressable market by region ('24E)




Upper Extremities segment does not include shoulder replacement, elbow replacement and sports segment, which Medartis does not

Lower Extremities segment includes F&A replacement, which Medartis does not currently

In the US, Medartis does not offer CMF yet

- Total addressable market for Medartis is USD 8-8.5bn, of which 54% is in US, 24% in EMEA and 22% in RoW
- Current USD market growth ca 8-11% in US, 6% in • EMEA and 3-5% in APAC & Latam. Volume growth in APAC & Latam is estimated to be high single digit
- Medartis has ca 4% market share of the addressable market: ca 1.5% in US, ca 9% in EMEA and ca 3.5% in RoW. In Upper Extremities EMEA, Medartis has ca 20% market share with over 30% in Hand & Wrist












Positioning of Medartis within competitive landscape

Distribution power

- Large scale companies with over USD 500m sales and diversified product portfolios
- Examples: Zimmer Biomet, Synthes/J&J, Smith & Nephew, Stryker, Acumed, Arthrex
- Extremities only a small part of much larger portfolio, not main focus
- Advantage: strong hospital relationships, cross-selling from other segments into extremities
- Ongoing optimisation of cash flow • and costs and restructuring teams
- Average annual extremities growth: single digit



medartis

- Outgrowing market over last 3 years by 2-2.5x times each year
- Dedicated to innovation, Training & Education and superior logistics & customer service
- Diversified product portfolio
- Global reach with own direct subsidiaries
- Focus on extremities
- Profitable & cash flow positive

Competitive pricing


- Value players with competitive pricing and good quality
- Examples: ITS, Hofer, Orthotech, GMReis, AAP and others, mostly local providers;
- Lower production and distribution costs, often focused R&D investments
- Challenge to build global scope, mostly working with distributors

medartis

Innovation edge

- Focused "young" players: High innovation pipeline
- Examples: Paragon 28, Treace Medical, Field Ortho, Newclip, Keri Medical, Skeletal Dynamics
- Often focused on region and/or product area (e.g. Foot & Ankle), often mostly working through distributors
- Huge range from "small" (e.g. Field • Ortho) to "big" (e.g. Paragon28)
- Often more focus on strong growth than profitability and cash generation














Investor Presentation | November 2024

medartis

The market

Medartis today


Transformation towards higher growth

Summary and key takeaways






Sales per segment and region



- Complete portfolio for upper extremities as well as covering 60% of lower extremities. Completely renewed CMF portfolio
- Market leader in Upper Extremities with over 30% market share in Hand & Wrist
- New Foot 2 system recently introduced to increase Lower Extremities sales
- CMX digital platform allows planning of procedures as well as individualised design for products and templates

Investor Presentation | November 2024

medartis




Medartis sales by region (H1 '24)

- EMEA: ~18% growth. Strong DACH region; increasing momentum in UK, France, Spain & Poland
- US: ~21% growth in H1, mostly driven by upper extremities business. Market growth estimated 10-12%
- APAC: only moderate growth (3.1%) following further Australian price cuts. Japan business currently taken over from former distributor
- LATAM business dropped due to Brazilian sales decline, following recent insurance merger and negotiation of contracts




15-20% annual growth since Covid*


EMEA




USA



APAC



LATAM




* 2019-2020 was affected by Covid, arrows show CAGR 2020-2023 growth at CER

Investor Presentation | November 2024

medartis

Total Group







Successful market entry in Spain since 2021



- Spanish team started in 2021 from scratch in the middle of Covid. Before that, Medartis had a small business with local distributor
- Team has systematically built market presence
- Spanish addressable market size: ~EUR 50m, attractive high-price segment
- HQ in Barcelona, additional sales office in Madrid
- Staff: ~30 FTEs highly motivated with winning mindset •
- Selling all products have also built strong lower extremities footprint
- 2024 FC approaching EUR 10m (>40% again)
- Business has been profitable since 2023

\rightarrow Generating growth by building direct markets





Current market challenges in Australia and Brazil



- Australia has faced reimbursement price cuts in 3 tranches since 2022, directly following Covid and very strict quarantine restrictions
- Total impact on top line since 2022 of \sim 20-25%, depending on product. Almost no market growth in value terms since then
- Medartis has fostered its market share, also as some \bullet traditional players have reduced their commitment to Australia. However, some new players are also aggressively trying to win business in Australia
- Medartis has adjusted to competitive dynamics and ulletbuilt-up more flexible channel coverage to address pricecut induced margin pressure: hybrid business model implemented during 2023 with good start in 2024



- Brazil grew about 20-25% annually post Covid, reflecting ulletstrong management and winning culture after taking over business from former distributor
- Current team size more than 70 FTEs, hybrid business • model with direct sales in Sao Paulo, Belo Horizonte and Porto Alegre – wider country covered by distributors
- In 2024 insurance merger caused need to re-negotiate ulletpricing with hospitals directly
- This has led to high pricing pressure on selected elective ulletprocedures (mostly CMF)
- Medartis expects accelerated growth in 2025, also based on some anticipated new product registrations





H1 performance at a glance

13.1%

group growth (core) excl. 3rd-party manufacturing

17.8%

EMEA growth vs 5-6% market growth

83.3%

core gross margin* (excl. 3rd-party manufacturing) 17.8%

core EBITDA margin* (vs 14.3% in PY)

*More detailed information in appendix

Investor Presentation | November 2024

medartis

20.6%

US growth vs 11-12% market growth

3.1% / -9.5%

APAC / LATAM growth defending or increasing market share despite external challenges

CHF 2.2_m

cash flow before M&A / financing (vs CHF -11.9m in PY)

core EBIT margin* (vs. 4.4% in PY)

8.5%








Organizational progress: Operations and processes

- After opening of high-capacity clean room several efficiency projects were launched to further improve core gross margin (currently >81%). Recent achievements: internalisation of sterile (and non-sterile) packaging – significant cost reduction potential
- NSI manufacturing plant in Warsaw allows further scaling ulletonce capacity limits in Basel are reached in 2027. Duplication of processes into US is ongoing - selected products can already be produced in the US
- Ongoing reduction of inventory levels after new process implementation with MDR hub for EMEA
- Successful management of hostile cyberattack in 2023, ulletsecurity improved massively since then, insurance coverage of damage expected by year-end
- New SAP S4 Hana go-live executed in May 2024 basis for ulletfurther efficiency
- Next steps: Set management efficiency improvements to further optimize capital employment









Investor Presentation | November 2024

medartis

The market

Medartis today

Transformation towards higher growth

Summary and key takeaways





Channel building in the US



- US growth execution
- and secure quality of surgeon coverage
- \bullet experts and Medartis own product specialists
- lacksquarecandidates evaluated, interview process has started
- More detailed update to follow in March 2025 ullet

medartis

Key learning from NSI acquisition is that channel building remains priority #1 for

• Since 2024 ongoing review of distributor portfolio – replace non-performing distributors and target high growth with all new distributors

• This process takes time and has to be done smoothly in order to protect topline

Additionally: hire of talents to strengthen team with highly experienced US market

 Specifically, preparation for Keri channel building: Hire of dedicated field force, build KOL network – close cooperation with Keri Medical to prepare later launch

Ongoing search for new General Manager is already priority for incoming CEO –




14

Ongoing innovation as growth driver

Foot 2 System

- Hallux and Midfoot System 2.8 enhanced flexibility, precision and adaptability, more options for corrections
- Mid- and Hindfoot System 2.8/3.5 unparalleled precision and control through unique independent plate and wedge positioning
- Fusion 3.5 System excellent precision in compressing individual joints and versatile range of adaptable plates



CCS line extensions

- Additional fully threaded screws, new lengths and improved thread design
- Optimized screw tip and thread design \bullet minimize insertion torque, allowing precise screw placement and enhancing user experience



Investor Presentation | November 2024

medartis


Dorsal Olecranon System 2.8

- Delivery of entire system (same tool basis, same screws, based on one single and consistent treatment concept)
- Estimated market potential >CHF 10m
- Full launch in April 2025
- Complementing the existing elbow portfolio (which is now one of the most comprehensive plate systems in the market) to close an indication gap - the design is set apart by its anatomical shape and a specific focus on coronoid support
- Dorsal plating is gold standard in olecranon fixation especially for the trauma surgeons

Scaphoid plates

• Unique scaphoid plate portfolio was extended with two additional sizes to better cater for differences in scaphoid size and shape











15

Digitalization as an enabler for further growth


- New digital technologies and patient-specific solutions support for the treatment of various indications including very complex cases to meet the individual anatomical needs of each patient
- CMX is an integrated service that supports workflow prior to and during the surgery, together with the most suitable plates and operating tools
- CMX accompanies the cases from initiation to intervention: everything is accessible directly from a browser

CMX Portal 3D Viewer

Enables the surgeon to analyse their 3D planning data in a sophisticated way. In the 3D Viewer the preoperative plan as well as pre-operative situation can be viewed from all angles.

CMX Portal Chat

The CMX Portal Chat enables the surgeon to communicate with their **CMX Clinical Product** Engineer at any time.



CMX Procedure

Registration login


medartis

CMX Portal Action Indicator


Clear visual indication if an action from the surgeon is required in order to go ahead with the case planning.

CMX Portal 3D Models

Lists all the 3D parts in the pre-operative situation or the planned outcome model.










Going direct in Japan – a high conviction market



- The Spanish success story shows that we can capture much value out of existing markets with a successful going direct
- In 2023 Medartis Board of Directors decided to go fully direct in Japan
- In summer 2024 the transfer from Medartis' former Upper Extremities \bullet distributor to a direct business setup started
- Experienced General Manager from the industry (>20 years' experience) \bullet recently started and is building team (plan to increase from 15-50 FTEs)
- We have additionally introduced our sterile product offer as a competitive ulletedge
- As from 2025 we expect Japan to grow strongly and start to become a ulletcountry of relevant absolute size for Medartis globally

medartis



17

Preparing to launch KeriTouch in the US

- Successful partnership with Keri Medical over the last 3 years generating high growth in selected markets (Germany, Austria & UK)
- Since H2 2024 KeriTouch has been also launched in Australia expected growth driver for 2025 and beyond
- KeriTouch is a unique product in new market with >USD 300m market potential. Keri has fostered its success with dedication to medical education, systematic KOL community building, and strong leverage with experienced sales force with high product expertise
- Keri targets FDA approval for KeriTouch during H1 2025
- Medartis has already secured distribution rights for the US since entering the partnership with Keri Medical in 2020
- Since 2020 Medartis has increased its shareholder stake from 25% to 47%, with the option to acquire the rest of the shares after the FDA approval
- Potential full acquisition could add visible growth: Keri's existing business is slightly accretive to Medartis







Redefining the addressable market



- geographic regions at premium pricing
- far
- offer solutions at different price points
- Central & Eastern Europe is large
- or partnerships with existing value players

medartis

Medartis has developed best-in-class products and sells them successfully in all

However, in some markets significant market potential remains unaddressed so

Recent insurance changes in Brazil have demonstrated how important it is to

• The potential of the so-called "value segment" in Latam, South-East Asia and

• Medartis will explore opportunities to address this market segment more systematically, either with own simplified product offers at a lower price point,





Financing strategy to support strong growth



- ulletremains committed
- Market challenge: current free float is too small liquidity is dry \bullet
- Over the last 2 years, we have used smaller "events" to execute rights issues to increase liquidity
- 2024 inaugural convertible issue to pre-finance Keri has "tapped" additional investor segment ulletand generated USD 500m investor demand
- Operational financing needs are fully covered with bank lines -so far undrawn \bullet
- We will use any potential upcoming acquisitions (e.g. technology add-ons) to envisage further rights issues (<CHF 50m), subject to capital market conditions
- \checkmark Minimization of dilution for existing shareholders gradual increase of liquidity and free float




medartis

Stable shareholder basis with Founder Thomas Straumann still holding ~45% of shares -



20



Investor Presentation | November 2024

medartis

The market

Medartis today

Transformation towards higher growth

Summary and key takeaways





Summary and key takeaways

Extremities market remains attractive niche in orthopaedics with above average growth

Medartis has systematically outgrown the market and won market share

2

Increased efficiency, cost structure and capital employment have improved intrinsic cash flow generation

3

Growth focus US more management capacity to strengthen commercial channels

Innovation strategy combines internal development & external partnering / M&A

medartis

5

2024 is a transformational year with unexpected challenges in Australia and Brazil

4

H1 2024 showed above-average growth in both EMEA and the US

Keri Medical: preparing for launch of Touch prosthesis in the US and potential full acquisition

8

New CEO just joined and will present growth acceleration strategy in March 2025







Thank you



Appendix H1 results: Core business with attractive margins

In CHFm	As reported	NSI revaluation (1)	3rd party business (2)	Other non-core (3)	Core
Net Sales	111.5		(3.9)		107.6
Costs of goods sold	(22.0)		4.0		(17.9)
Gross profit	89.6		0.1		89.7
Орех	(93.1)	10.1	0.1	2.4	80.5
Other income	7.0	(7.0)			0
Operating profit (EBIT)	3.5	3.2	0.2	2.4	9.2
Depreciation & amortization	20.4	(10.1)	(0.4)		9.9
EBITDA	23.9	(7.0)	(0.2)	2.4	19.1

Margins	As reported	NSI revaluation	Core
Gross margin	80.3%		83.3%
EBIT margin	3.1%	+2.9%	8.5%
EBITDA margin	21.4%	-6.3%	17.8%

- NSI revaluation triggered an impairment of intangible assets (CHF 10.1m) and parallel relief of contingent liability for future milestone payments
 CHF 3.9m sales from (non-strategic) 3rd party manufacturing (legacy business from acquired NSI)
 Other non-core items include a one-off payment to take over JP distributor business as well as costs for the announced CEO change

Investor Presentation | November 2024

medartis



24